What's New: Every Page Checked Against the FDA & the Trial Registry
October was a month of new pages and, above all, of checking: every approval, every trial description, every “recruiting” label.
Every FDA Approval Since 2023, Checked Against Our Pages
When a treatment is approved, the “approved options” section of a page is often the first thing a patient reads, and AI assistants quote it too. So this month we took the FDA's full list of cancer and blood-cancer approval announcements from January 2023 to the end of October, and checked each one against the disease, drug and mechanism pages where it should appear.
Most were already there, but dozens were not, and we added them. A few examples of what you'll now find:
- Lung cancer: the approved options are now laid out by mutation — EGFR, EGFR exon 20, ALK, ROS1, HER2, KRAS G12C, MET, NRG1, RET, BRAF and NTRK — plus the immunotherapy options before and after surgery.
- Prostate cancer: talazoparib with enzalutamide for metastatic hormone-sensitive disease with HRR gene mutations (approved October 26), and niraparib with abiraterone for BRCA2-mutated disease.
- Colorectal cancer: atezolizumab added to chemotherapy after surgery for stage III mismatch-repair-deficient colon cancer (October 8), dostarlimab for mismatch-repair-deficient locally advanced rectal cancer (October 19), and the options for cancer that has stopped responding to standard treatment.
- CLL: pirtobrutinib as a first treatment (October 2), and venetoclax with acalabrutinib.
- HER2-positive breast cancer: tucatinib added to maintenance after initial treatment (October 7).
- Nasopharyngeal carcinoma: the two approved first-line immunotherapy options, toripalimab and penpulimab, each with gemcitabine and platinum chemotherapy.
Going forward, each page is checked for new approvals every time it is refreshed, and a weekly scan of FDA cancer actions flags anything that needs adding.
Every Trial Description, Checked Against the Registry
Each disease page describes the trials it lists in a line or two: the drug, the cancer, the biomarker, the setting. This month we compared those descriptions, across about 2,500 trial links, with each trial's own record on ClinicalTrials.gov.
We corrected the ones that didn't match. For example, a lung cancer trial for HER2 mutations had been described as an EGFR trial, and two trials for brain metastases had been described as early-stage breast cancer trials. We also relabeled trials that are no longer recruiting but were still shown as if they were. This check now runs every time a page is refreshed.
Why it matters: a wrong label can send you to a trial you can't join, or hide one you can. Before contacting a trial, it's always worth reading its eligibility on ClinicalTrials.gov — but the summary on our page should already point you the right way.
New Pages
- Hodgkin lymphoma — our first page for it, built around the March 2026 approval of nivolumab with AVD chemotherapy as a first treatment for advanced classical Hodgkin lymphoma, with the recruiting trials grouped by situation.
- Metastatic castration-resistant prostate cancer — a dedicated page for the setting where PSMA radioligands, PARP inhibitors and cell therapies are being tested, with the approved options explained first.
- HER2-low breast cancer — for tumors with low but detectable HER2, a group that now has its own approved treatments and trials.
- Telisotuzumab adizutecan — an antibody-drug conjugate aimed at c-Met, which received two FDA Breakthrough Therapy Designations in October.
Trial Guides for Specific Mutations
Search data showed that many visitors are looking for trials that match one specific mutation, so we wrote two guides:
- KRAS G12R and G12V pancreatic cancer — which trials accept each variant. One practical finding: some of the new “pan-KRAS” drug trials list the mutations they accept and leave G12R out, so the guide lists the options that do include it.
- EGFR exon 20 lung cancer — the two approved drugs and the recruiting and upcoming trials for this less common EGFR mutation, which responds poorly to standard EGFR pills.
Clearer Results & Smaller Improvements
- Accurate randomization notes on trial cards. Your result cards now say a trial “may randomize you to standard treatment” only when the trial's registered design actually includes a standard-treatment group — and no longer say it for single-group trials where everyone gets the study treatment.
- Trials built for your cancer rank first on ties. When a trial designed specifically for your cancer and a broad multi-cancer trial score the same, the specific one now comes first.
- More reliable reading of eligibility criteria. The system now finds the inclusion and exclusion sections of a trial's criteria however they're capitalized or titled, and treats a requirement as “unclear” rather than “not met” when your profile simply doesn't mention it.
- Better recognition of how you type your diagnosis. Spelling variants of the same disease now lead to the same questions, and IDH-mutant tumors entered as “glioblastoma” are handled under the current WHO classification as astrocytoma.
- Fixes to the questions. The staging options for stomach and liver cancer were corrected, and country names such as Czechia and Türkiye are now recognized.
- Reliability and security. We added fair-use limits that keep the free search available for everyone, and updated the software the site runs on.
Try It
Questions or feedback? Contact us